Description

Returning for a second study this month, the JHLT Digital Media Editors invite first author Charlotte Van Edom to discuss the paper, "Apixaban plasma levels in patients with HeartMate 3 support."

As a cardiologist in training and a PhD candidate at the University Hospitals Leuven in Belgium, Van Edom's work focuses on hemocompatibility and mechanical circulatory support, covering both short-term and long-term support.

The episode explores:

• The evolution of the use and understanding of direct oral anticoagulants (DOACs) during LVAD support, including the increased focus on Factor Xa inhibitors
• Encouraging findings from the study and what clinical practices might need to change if introducing apixaban
• Additional studies exploring DOACs in LVAD patients

For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.

Treat or research pulmonary vascular diseases? Check out the first April episode for a study on sotatercept in PAH patients.

Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.